AURX on OTC

Nuo Therapeutics, Inc.

American surgical and medical instruments and apparatus company. Summary from the record

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with IceCure Medical, OSR Health, Inc. or Tenon Medical, Inc., or pick any stock.

  • TickerAURX on OTC2
  • IndustrySurgical & Medical Instruments & Apparatus2
  • HeadquartersGaithersburg, United States2
  • Incorporated inDE3
  • Business address8285 El Rio, Suite 190, Houston, Tx 770543
  • Filer categoryNon-accelerated filer, Smaller reporting company3
  • Legal formCorporation2
  • LEI549300H0QI00R4LH8U412
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressC/O COGENCY GLOBAL INC., 19904 Dover, United States2
  • Registered withDivision of Corporations, Department of State, 28908682

See how the biggest companies compare on our leaderboards

Nuo Therapeutics, Inc. is a Delaware corporation organized in 1998 under the name Informatix Holdings, Inc. In 1999, Autologous Wound Therapy, Inc., an Arkansas Corporation, merged with and into Informatix Holdings, Inc. and the name of the surviving corporation was changed to Autologous Wound Therapy, Inc. In 2000, Autologous Wound Therapy, Inc. changed its name to Cytomedix, Inc. (“Cytomedix”). In 2001, Cytomedix, filed for bankruptcy, from which it emerged in 2002 under a Plan of Reorganization.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

66.9%Gross margin5
-76.0%Operating margin5
-75.8%Net margin5
142.7%Revenue growth, 20255
-$1.1MFree cash flow5

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Product brought in 67% of the revenue Nuo Therapeutics, Inc. broke down this way in fiscal 2025.

  1. Product$3.1M567%up 126% from 2024
  2. Aurix and Private Label Kits$1.2M627%
  3. License$225.0K75%
  4. Aurix and Private Label Centrifuge Devices$77.0K62%
Products and services by year
Products and services20242025
Product$1.4M$3.1M
Aurix and Private Label Kits$1.2M
License$0$225.0K
Aurix and Private Label Centrifuge Devices$77.0K

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue19¢$1.1M
  • Selling, general and admin81¢$4.7M

Out of $3.3M in revenue.5 The company lost money this year.

Financial statements

Revenue8910115$3.3M in 2025+2167% since 2019
0$1.0M$2.0M$3.0M$4.0M2019: $146.2K$146.2K20192020: $0$020202021: $0$020212022: $112.2K$112.2K20222023: $608.5K$608.5K2023+442%2024: $1.4M$1.4M2024+124%2025: $3.3M$3.3M2025+143%
Gross profit8910115$2.2M in 2025+6927% since 2019
0$1.0M$2.0M$3.0M2019: $31.6K$31.6K20192020: $0$020202021: $0$020212022: $93.0K$93.0K20222023: $482.4K$482.4K2023+419%2024: $1.1M$1.1M2024+120%2025: $2.2M$2.2M2025+109%
Operating income8910115-$2.5M in 2025+160% since 2019
-$4.0M-$3.0M-$2.0M-$1.0M02019: -$969.2K-$969.2K20192020: -$378.1K-$378.1K2020−61%2021: -$90.7K-$90.7K2021−76%2022: -$3.3M-$3.3M2022+3562%2023: -$3.2M-$3.2M2023−5%2024: -$2.5M-$2.5M2024−22%2025: -$2.5M-$2.5M2025+2%
Net income8910115-$2.5M in 2025+110% since 2019
-$4.0M-$3.0M-$2.0M-$1.0M02019: -$1.2M-$1.2M20192020: -$90.9K-$90.9K2020−92%2021: -$90.7K-$90.7K2021−0%2022: -$3.2M-$3.2M2022+3398%2023: -$3.2M-$3.2M2023−0%2024: -$2.3M-$2.3M2024−27%2025: -$2.5M-$2.5M2025+8%

Every line of the income statement as filed: the last 2 fiscal years, latest first.5

Period ending2025-12-312024-12-31
Revenue$3.3M$1.4M
Costs of sales$1.1M$302.8K
Selling, general and administrative$4.7M$3.5M
Total operating expenses$4.7M$3.5M
Loss from operations-$2.5M-$2.5M
us-gaap_GrossProfit$2.2M$1.1M
Interest income (expense), net-$804$105
Gain on settlement of legacy accounts payable obligations$0$133.6K
Other income$5.2K$402
Loss before benefit for income taxes-$2.5M-$2.3M
Net loss-$2.5M-$2.3M
Basic and diluted (in dollars per share)-$0.05-$0.05
Basic and diluted (in shares)47.3M shares45.4M shares

Compare Nuo Therapeutics, Inc. with another company

Leadership

Who has led Nuo Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Kshitij Mohan2006–2008
  2. Martin P. Rosendale2008–2014
  3. David Emerson Jorden2016–now

Chief financial officer

  1. Andrew Scott Maslan2006–2012
  2. Steven A. Shallcross2014
  3. David Emerson Jorden2015–now

Chief operating officer

  1. Martin P. Rosendale2008
  2. Peter Clausen2022–now
2010201520202025
Board members and other officers (22)

Former names

  • Nuo Therapeutics, IncNov 13, 2014 to Dec 23, 20143
  • CYTOMEDIX INCAug 14, 2000 to Oct 8, 20143
  • AUTOLOGOUS WOUND THERAPY INCApr 12, 2000 to Apr 10, 20003
  • AUTOLOGOUS WOUND TRERAPY INCDec 10, 1999 to Mar 23, 20003

Timeline

  1. Jul 29, 2016New chief executive David Emerson Jorden becomes CEO12
  2. Sep 9, 2008New chief executive Martin P. Rosendale becomes CEO13
  3. Aug 18, 2006New chief executive Kshitij Mohan becomes CEO14
  4. Apr 29, 1998Founded Nuo Therapeutics, Inc. is founded2

Filings

140 filings to the SEC since October 2021: 6 annual reports, 16 quarterly reports, 21 major events, 60 insider forms, 11 large holders, 7 private raises, 19 other. The latest 20:

  1. Oct 6, 20264 FORM 4 - SCOTT PITTMAN - SECOND FUNDING WARRANTS EDGAR
  2. Oct 6, 20268-K EDGAR
  3. Aug 31, 20264/A EDGAR
  4. Aug 28, 20264 EDGAR
  5. Aug 17, 20268-K EDGAR
  6. Aug 14, 202610-Q EDGAR
  7. Jul 2, 20264 EDGAR
  8. Jul 2, 20264 EDGAR
  9. Jul 2, 20264 EDGAR
  10. Jul 2, 20264 EDGAR
  11. Jul 2, 20264 EDGAR
  12. Jun 5, 20264 EDGAR
  13. Jun 3, 2026SCHEDULE 13D/A EDGAR
  14. Jun 3, 20268-K EDGAR
  15. Jun 2, 20264 EDGAR
  16. Jun 2, 20264/A EDGAR
  17. May 14, 20268-K EDGAR
  18. May 14, 202610-Q EDGAR
  19. Mar 30, 202610-K EDGAR
  20. Feb 12, 2026SCHEDULE 13G/A EDGAR

The 140 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

10 open-market trades by officers, directors and large owners since October 2021: 8 buys and 2 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Aug 28, 2026JORDEN DAVID EMERSONCEO/CFOBuy7,984$1.09$8.7KForm 4
Aug 27, 2026JORDEN DAVID EMERSONCEO/CFOBuy789$1.07$844Form 4
Nov 28, 2025JORDEN DAVID EMERSONCEO/CFOSale200,000$1.50$300.0KForm 4
Jul 30, 2025SHEEDY CHARLES E10% ownerBuy133,333$1.50$200.0KForm 4
Sep 18, 2024SHEEDY CHARLES E10% ownerBuy125,000$0.75$93.8KForm 4
May 20, 2024SHEEDY CHARLES E10% ownerBuy100,000$0.75$75.0KForm 4
Dec 19, 2023SHEEDY CHARLES E10% ownerBuy150,000$0.50$75.0KForm 4
Aug 1, 2023SHEEDY CHARLES E10% ownerBuy62,500$2.00$125.0KForm 4
Nov 9, 2022JORDEN DAVID EMERSONCEO/CFOSale162,500$1.50$243.8KForm 4
Apr 29, 2022SHEEDY CHARLES E10% ownerBuy804,868$1.00$804.9KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

  • Scott M. PittmanSCHEDULE 13D/A, 4 filings Jul 5, 2022 to Jun 3, 202641
  • Paul Anthony JacobsSCHEDULE 13G/A, 3 filings Feb 14, 2024 to Feb 12, 202642
  • James E. FlynnSC 13G/A, 2 filings Feb 12, 2024 to Nov 14, 202443
  • Charles E. SheedySC 13D/A, 1 filing Jul 5, 202244
  • David Emerson JordenSC 13D, 1 filing Jul 5, 202245

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Jul 30, 2025Raised $791,418 in a private offering of equity Form D: 9 investors so far Form D
  2. Sep 19, 2024Raised $849,125 in a private offering of equity Form D: 10 investors so far Form D
  3. May 20, 2024Raised $650,875 in a private offering of equity Form D: 11 investors so far Form D
  4. Dec 19, 2023Raised $962,500 in a private offering of equity Form D: 9 investors so far Form D
  5. Aug 1, 2023Raised $1 million in a private offering of equity Form D: 9 investors so far Form D
  6. May 18, 2022Raised $407,757 in a private offering of equity Form D: 6 investors so far Form D
  7. Apr 29, 2022Raised $3.5 million in a private offering of equity Form D: 26 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Ancora Advisors LLC4,700$4.3K0.0%No change

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45